CATTANEO, DANIELE
CATTANEO, DANIELE
Dipartimento di Oncologia ed Emato-Oncologia
Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis
2026 B. Mora, M. Franchi, L. Margotto, O. Leoni, D. D'Ippoliti, E. Carloni, I. Cozzi, E. Santelli, F. Gemmi, C. Szasz, M. Maffioli, C. Gurnari, E. Attardi, D. Cattaneo, M. Bortolotti, N.S. Fracchiolla, A. Iurlo, G. Corrao, M.G. Della Porta, A.M. Vannucchi, M.T. Voso, P. Guglielmelli, F. Passamonti
Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis
2026 F. Palandri, G. Caocci, E. Abruzzese, M. Tiribelli, E. Morsia, M. Farina, G. Benevolo, E. Beggiato, B. Martino, N. Pugliese, A. Tieghi, M. Crugnola, G. Binotto, F. Cavazzini, A. Iurlo, A. Isidori, A. Dedola, E. Scalzulli, A. Duminuco, D. Cattaneo, R.M. Lemoli, C. Bosi, D. Cilloni, M. Bocchia, F. Pane, C. Sartor, F.H. Heidel, M. Breccia, F. Branzanti, G.A. Palumbo, M. Bonifacio, E.M. Elli
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis
2026 B. Mora, F. Palandri, P. Guglielmelli, A.T. Kuykendall, M. Maffioli, A. Iurlo, V. De Stefano, S. Salmoiraghi, T. Devos, F. Itri, F. Cervantes, J. Kiladjian, M.G. Della Porta, F. Albano, J. Gotlib, G. Benevolo, M. Caramella, M. Ruggeri, E. Rumi, D.M. Ross, C. Pessina, I. Colugnat, F. Orsini, G. Micucci, G. Rotunno, R.S. Komrokji, D. Cattaneo, P. Chiusolo, M. Bortolotti, T. Barbui, D. Cilloni, M. Breccia, G.A. Palumbo, F. Branzanti, L. Margotto, M. Franchi, A.M. Vannucchi, F. Passamonti
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study
2026 A. Iurlo, D. Cattaneo, C. Fava, F. Castagnetti, M. Bonifacio, M. D'Adda, M.C. Miggiano, I. Capodanno, C. Elena, L. Levato, A.R. Scortechini, F. Lunghi, M. Caramella, N. Orofino, M. Maffioli, V. Bellani, V. Bonuomo, S. Grano, G. Cotilli, E. Scalzulli, M. Dalmazzo, S.L. Crescenzi, L. Luciano, B. Martino, T. Intermesoli, D. Rapezzi, G. Binotto, M. Tiribelli, D. Consonni, F. Pane, G. Saglio, C. Gambacorti‐passerini, M. Breccia, G. Rosti
Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome
2026 A. Ciavarella, L. Baronciani, O. Seidizadeh, P. Colpani, E. Ingenito, D. Cattaneo, M.T. Pagliari, A. Truma, A. Iurlo, S.M. Siboni, F. Peyvandi
Thermo‐Chemically Modified Silk Scaffolds Reveal Niche‐Driven Regulation of Hematopoiesis and Fibrosis
2026 C.A. Di Buduo, C.P. Miguel, G. Della Rosa, V. Abbonante, S. Diprima, D. Tosi, M. Filibian, D. Cattaneo, J.K. Sahoo, N. Tirelli, A. Iurlo, U. Gianelli, D.L. Kaplan, A. Balduini
Characterization of a Newly Discovered Non‐Coding Variant in the EPO Gene Identified in Two Unrelated Italian Pedigrees With Erythrocytosis
2026 B. Mora, V. Bellani, D. Pietra, E. Tagliaferri, D. Cattaneo, O. Borsani, A. Iurlo, E. Fermo, P. Bianchi, E. Rumi, F. Passamonti
Reply to: Association between nilotinib-induced hyperbilirubinemia and UGT1A1 polymorphisms in a chronic myeloid leukemia patient
2025 D. Cattaneo, A. Iurlo
The 2024 Three‐Strata Baseline Anemia Definition of the Revised IWG‐ELN Criteria Dissects Survival in Ruxolitinib‐Treated Myelofibrosis Patients
2025 M. Maffioli, B. Mora, A. Iurlo, E.M. Elli, M.C. Finazzi, M. Farina, E. Rumi, M. Caramella, M.C. Carraro, M. D'Adda, A. Molteni, E. Mimiola, F. Lunghi, A. Vismara, M. Ubezio, M.C. Di Chio, M. Anghilieri, D. Cattaneo, M.G. Della Porta, L. Bertù, M. Coscia, F. Passamonti
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera
2025 T. Barbui, A. Ghirardi, V. Empson, F. Fenili, G.G. Loscocco, A. Condorelli, A. Iurlo, D. Cattaneo, E. Rossi, V. De Stefano, P. Guglielmelli, C. Klade, H. Gisslinger, A. Rambaldi, J.M. Scandura, A.M. Vannucchi
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
2025 V. De Stefano, F. Passamonti, F. Palandri, F. Ramundo, E. Rossi, S. Betti, L. Fagiolo, P. Guglielmelli, D.P. Abagnale, N. Pugliese, D. Cattaneo, A. Iurlo, F. Branzanti, A. Dedola, H. Catellani, A. Tieghi, M. Basso, E. Calistri, E.M. Elli, E. Masselli, E. Morsia, G. Benevolo, M. Breccia, V. De Fazio, M. Di Perna, M. Marchetti, M. Santoro, A. Tafuri, C. Castiglioni, C. Rotella, S. Siragusa, A.M. Vannucchi, N. Null
SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability
2025 M. Mancini, S. De Santis, C. Monaldi, F. Castagnetti, M. Iezza, A. Iurlo, D. Cattaneo, S. Galimberti, M. Cerrano, I. Capodanno, M. Bonifacio, M. Rossi, C. Agostinelli, M. Meggendorfer, T. Haferlach, M. Cavo, G. Gugliotta, S. Soverini
Circulating Levels of PF4/CXCL4 in Patients With BCR::ABL1-Negative Myeloproliferative Neoplasms: A New Potential Prognostic Factor for Disease Progression
2025 V. Bellani, D. Cattaneo, V. Abbonante, C. Bucelli, S. Stella, B. Mora, A. Malara, U. Gianelli, A. Balduini, A. Iurlo
Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy
2025 A. Iurlo, C. Bucelli, T. Intermesoli, C. Elena, M. D'Adda, E. Agostani, C. Fiamenghi, M. Maffioli, N. Orofino, F. Lunghi, A. Gardellini, M.C. Carraro, A. Inzoli, F. Gigli, R. Palazzolo, V. Bertolli, D. Cattaneo, E.M. Pungolino, C. Gambacorti-Passerini
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study
2025 A. Sicuranza, P. Pacelli, A. Santoni, E. Abruzzese, D. Cattaneo, A. Iurlo, L. Luciano, S. Galimberti, V. Giai, O. Mulas, G. Caocci, F. Sorà, I. Capodanno, M. Crugnola, A. Gozzini, S. Russo, M. Annunziata, C. Fozza, A. Cartocci, S. Fredducci, E. Pacini, A.M. Liberati, M. Defina, E. Bestoso, C. Marzano, D. Tocci, T. Miracapillo, C. Turriziani, K. Peccia, D. Raspadori, M. Bocchia
Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options
2025 A. Iurlo, D. Cattaneo, U. Gianelli, F. Passamonti
Granuloma annulare-like pseudohistiocytosis: a specific manifestation of ETV6::SYK-rearranged myeloid neoplasm with eosinophilia
2025 G.A. Croci, D. Cattaneo, S. Tabano, I. Catusi, M. Zappa, C.A. Maronese, N. Bolli, A.V. Marzano, A. Iurlo
The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective
2024 C. Pescia, G. Lopez, D. Cattaneo, C. Bucelli, U. Gianelli, A. Iurlo
Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
2024 D. Cattaneo, N. Galli, C. Bucelli, C.A. Fidanza, V. Bellani, S. Artuso, P. Bianchi, D. Consonni, F. Passamonti, A. Iurlo
Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases
2024 D. Cattaneo, A. Marchetti, C. Bucelli, N. Galli, M. Lionetti, V. Bellani, U. Gianelli, F. Passamonti, N. Bolli, A. Iurlo